Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Asthma Drugs Market
With a compound annual growth rate (CAGR) of XX% from 2024 to 2033, the global market for asthma medications was valued at US$ XX billion in 2023 and is projected to reach US$ XX billion by 2033. The market for asthma medications has grown as a result of the substantial risk factor for asthma that air pollution poses. It also aggravates pre-existing diseases and causes new cases of asthma. Healthcare professionals receive training from the WHO that emphasises the crucial connection between asthma and air pollution and offers helpful tips for minimising exposure. The Comprehensive Primary Health Care initiative of Ayushman Bharat - Health and Wellness Centres is supporting the preventive aspects of noncommunicable diseases (NCDs), such as asthma and Chronic Obstructive Pulmonary Diseases (COPD). This initiative encourages wellness activities and focused community-level communication. Under the National Health Mission (NHM), the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) finances awareness-raising activities. This allows States and Union Territories to carry out these programs in accordance with their Programme Implementation Plans (PIPs). Asthma is the most frequent chronic illness among children and a common non-communicable disease (NCD), which drives demand for asthma medications.
Market Overview Due to the chronic nature of asthma, which affects individuals of all ages and causes inflammation and muscle tightness around the airways, the market for asthma medications is expanding quickly. Symptoms of asthma include coughing, wheezing, shortness of breath, and tightness in the chest. Even while asthma is still underdiagnosed and undertreated, especially in low- and middle-income nations, the illness is manageable with the right care. The main course of treatment entails using inhalers, which provide medication directly to the lungs. Depending on the frequency of symptoms and kind of inhaler, daily use is frequently required. The effectiveness and convenience of using inhalers have increased with the addition of spacer devices, especially for youngsters and in emergency situations. There is a sizable unmet need that drives market expansion even though steroid inhalers are available in one third of low- and middle-income countries and bronchodilators in about half of public primary health care institutions. The need for efficient asthma therapies is increased by the fact that asthma is prioritised globally in both the UN 2030 Agenda for Sustainable Development and the WHO Global Action Plan for the Prevention and Control of NCDs. • In July 2023, Viatris announced the launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first FDA-approved generic version of Symbicort for people with asthma and chronic obstructive pulmonary disease, in partnership with Kindeva
• In January 2023, AstraZeneca's latest asthma launch filled a gap as generics chipped away at respiratory flagships
Key Insights
• North America led the global market with the highest market share. • By Medication, the quick relief medications segment has held the largest market share. • By Mode of Administration, the inhalers segment captured the biggest market share. • By Organization Type, the public segment is estimated to hold the highest market share. • By Application, the adults segment registered the maximum market share.
Regional Stance Market research study on asthma medications outlines opportunities for the industry in a number of regions, including Asia-Pacific, Latin America, Europe, North America, and the Middle East and Africa. The market for asthma medications is dominated by North America since asthma is becoming more and more common; in the US alone, 25 million people—20 million adults and 5 million children—are affected by the condition. About 1 in 13 Americans suffer from asthma, which is characterised by spells of coughing, wheezing, chest tightness, and shortness of breath, according to the Centres for Disease Control and Prevention. Since the condition affects people of all ages and frequently first manifests in childhood, there is a substantial market need for efficient asthma therapies in this area. Because asthma is becoming more common in emerging nations, the demand for asthma medications is expected to rise at a notable rate of growth in the Asia Pacific area. Only 33% of physicians and nurses work in rural India, where 65% of the population lives. This indicates a substantial healthcare discrepancy between urban and rural areas, as stated by the World Bank in 2021. Since the private sector employs the majority of the health workers, private facilities offer around 70% of outpatient care and 60% of inpatient treatment. The frequency of asthma is noticeably higher in rural regions, and it has a substantial impact on morbidity and mortality. Short-acting beta-agonists (SABAs), especially β2-agonists, are widely available over-the-counter and frequently overused in both urban and rural environments, including among paediatric patients. With an estimated 34 million asthma sufferers in India, it is crucial to make sure general practitioners are properly trained to identify and manage this respiratory ailment, filling a vital demand in the area.
Report Highlights By Technology Asthma drug sales are dominated by the quick relief pharmaceutical sector, which is credited with its ability to quickly relieve symptoms such chest tightness, coughing, wheezing, and constricted airways. Proventil HFA, ProAir HFA, Ventolin HFA, albuterol, Maxair, and Xopenex are good examples of quick-relief drugs. These drugs lower the intrinsic vagal tone of the airway and block muscarinic cholinergic receptors. Specifically, ipratropium bromide acts as an alternate bronchodilator for individuals who cannot tolerate short-acting beta-agonists (SABAs) and provides an added benefit to SABAs in moderate-to-severe asthma exacerbations. The reason this sector is so well-known is because these medications offer instant symptom relief, which makes them crucial for managing asthma.
By Mode of Administration Due to its ability to effectively transport medication to small airways, minimising systemic effects and requiring lower doses than oral steroids, inhalers hold the largest proportion of the market for asthma treatments. In addition to being affordable and safe, inhalers are also lightweight and easy to use. There are even non-breath activated versions of inhalers that are less expensive than dry powder inhalers. These small, hand-held devices are essential for managing asthma symptoms because they provide a range of options for effective symptom control. Since inhalers combine user convenience and effectiveness, their widespread use highlights their critical role in the administration of asthma treatment.
By End User Market for asthma medications is dominated by the public sector, which is greatly impacted by programs like the CDC's National Asthma Control Program (NACP), which strives to improve asthma patients' quality of life and health outcomes in the country. To enhance the tracking and trends of asthma rates, the NACP provides funding to governments, territories, cities, school programs, and non-profit organisations. These grant-funded initiatives provide asthmatic patients with educational materials and health professional training. With the goal of preventing 500,000 ER visits and hospital stays by August 2024, the CDC's Controlling Childhood Asthma and Reducing problems (CCARE) effort uses EXHALE techniques to minimise asthma and related problems in children. This extensive engagement of the public sector highlights the vital role that government-funded initiatives play in improving asthma management and stimulating the market demand.
By Application Due to the increasing use of long-acting beta-agonists (LABAs) in conjunction with inhaled steroids for the management of persistent asthma, the adults sector dominated the market for asthma medications. Long-acting beta-agonists (LABAs) like formoterol, salmeterol, and vilanterol provide relief for 12 hours or longer, which is longer than short-acting beta-agonists (SABAs). The majority of the time, inhalers that mix a steroid and a LABA—such as Advair, Breo, Dulera, and Symbicort—are recommended. Formoterol's fast action, similar to that of SABAs like albuterol, makes inhalers containing budesonide and formoterol (e.g., Breyna, Symbicort) useful both as daily controller drugs and for immediate symptom relief. This all-encompassing strategy for managing asthma highlights the vital role that these combination treatments play in the adult population, further solidifying their market supremacy.
Market Dynamics Driver Increased Awareness Market for asthma medications is expanding significantly due to changing diagnostic procedures that make it more difficult to assess changes in prevalence and heightened public awareness of asthma. Asthma prevalence appears to be on the rise globally, especially in urbanised areas, with children and teens in middle- and low-income nations showing a particularly marked increase in the disease. The trend of rising urbanisation indicates that asthma prevalence would probably continue to climb, notwithstanding the paucity of studies on the time trends of asthma prevalence among adults based on representative samples. The continuous rise in asthma cases, especially in cities, highlights the rising need for asthma medications, which is driving market growth.
Restraints Diagnostic and Management Challenges A number of significant obstacles, such as a lack of specialised diagnostic facilities, restricted access to spirometry, and the stigma attached to asthma, are impeding the market's growth for asthma medications. More obstacles to managing asthma in the Middle East and Africa (MEA) include an excessive dependence on short-acting β-agonists (SABAs), underprescription of inhaled corticosteroids (ICS), medication non-adherence, and insufficient insurance coverage for therapy. All of these limitations together restrict the ability to diagnose and treat asthma effectively, which limits the market's potential for growth.
Opportunities AIRSUPRA Approval Opens New Opportunities FDA's approval of AIRSUPRA in January 2023 represents a major market potential for asthma medications. AstraZeneca's first-in-class SABA/ICS rescue medication, AIRSUPRA, uses Aerosphere delivery technology to administer budesonide and albuterol in a fixed-dose inhalation. For people eighteen years of age and above, this novel drug is intended for use on an as-needed basis to treat and prevent symptoms of asthma as well as to avert severe asthma episodes. AIRSUPRA has been shown in clinical trials to be more effective than normal albuterol treatments in lowering the likelihood of severe exacerbations in people with moderate-to-severe asthma. With the launch of AIRSUPRA, unmet medical requirements are addressed and a great prospect to improve asthma management is presented, which could lead to significant increase in the market for asthma medications.
• In January 2024, AIRSUPRA (albuterol/budesonide) became available as the first and only FDA-approved anti-inflammatory rescue option for asthma
Recent Developments
• In February 2024, Xolair (omalizumab) was approved by the FDA as the first and only medicine for children and adults with one or more food allergies • In February 2024, GSK completed the acquisition of Aiolos Bio, which focuses on unmet treatment needs of patients with respiratory and inflammatory conditions • In March 2024, GSK joined AstraZeneca and Boehringer in capping US out-of-pocket inhaler prices at $35 per month • In March 2024, AstraZeneca announced plans to cap asthma and COPD medications at $35 a month
Key Players in the Asthma Drugs Market GlaxoSmithKline Pfizer Vectura Group Boehringer Ingelheim Roche Novartis Merck AstraZeneca Teva Pharmaceutical
Market Segmentation By Medication Quick Relief Medications Long-term Control Medications Others
By Mode of Administration Tablets and Capsules Liquids Inhalers Injections
By Organization Type Public Private
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
Table of content
1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. Asthma Drugs Market by Medication 4.1. Introduction 4.2. Asthma Drugs Market Size and Growth Rate by Medication (2021-2030) 4.3. Quick Relief Medications 4.3.1. Quick Relief Medications Market Size and Growth Rate (2019- 2030) 4.4. Long-term Control Medications 4.4.1. Long-term Control Medications Market Size and Growth Rate (2019- 2030) 4.5. Others 4.5.1. Others Market Size and Growth Rate (2021-2030) 4.6. Endoscopic Suturing Market Size and Growth Rate by mode of Administration (2021-2030) 4.6.1. Introduction 4.7. Tablets and Capsules 4.7.1. Tablets and Capsules Market Size and Growth Rate (2021-2030)
5. Liquids 5.1. Liquids Market Size and Growth Rate (2021-2030) 5.2. Inhalers 5.3. Inhalers Market Size and Growth Rate by Treatment Type (2021-2030) 5.3.1. Injections
5.8. Achalasia 5.8.1. Achalasia Market Size and Growth Rate (2021-2030) 5.9. Others 5.9.1. Others Market Size and Growth Rate (2021-2030)
6.2. Asthma Drugs Market Size and Growth Rate by Organization Type (2021-2030) 6.3. Public 6.3.1. Public Market Size and Growth Rate (2021-2030) 6.4. Private 6.4.1. Private Centers Market Size and Growth Rate (2021-2030)
7. Company Profiles 7.1. GlaxoSmithKline 7.1.1. Business Overview 7.1.2. Service Portfolio 7.1.3. Strategic Developments 7.1.4. Financial Overview
7.2. Pfizer 7.2.1. Business Overview 7.2.2. Service Portfolio 7.2.3. Strategic Developments 7.2.4. Financial Overview
7.3. Vectura Group 7.3.1. Business Overview 7.3.2. Service Portfolio 7.3.3. Strategic Developments 7.3.4. Financial Overview
7.4. Boehringer Ingelheim 7.4.1. Business Overview 7.4.2. Service Portfolio 7.4.3. Strategic Developments 7.4.4. Financial Overview
7.5. Roche 7.5.1. Business Overview 7.5.2. Service Portfolio 7.5.3. Strategic Developments 7.5.4. Financial Overview
7.6. Novartis 7.6.1. Business Overview 7.6.2. Service Portfolio 7.6.3. Strategic Developments 7.6.4. Financial Overview
7.7. Merck 7.7.1. Business Overview 7.7.2. Service Portfolio 7.7.3. Strategic Developments 7.7.4. Financial Overview
7.8. AstraZeneca 7.8.1. Business Overview 7.8.2. Service Portfolio 7.8.3. Strategic Developments 7.8.4. Financial Overview
7.9. Teva Pharmaceutical 7.9.1. Business Overview 7.9.2. Service Portfolio 7.9.3. Strategic Developments 7.9.4. Financial Overview
8. List of Tables and Figures Table Asthma Drugs Market Size and Market Share by Medication (2021-2023)
Table Asthma Drugs Market Size and Market Share by Medication (2023-2030)
Figure Quick Relief Medications Market Size and Growth Rate (2021-2030)
Figure Long-term Control Medications Market Size and Growth Rate (2021-2030)
Figure Others Market Size and Growth Rate (2021-2030)
Table Asthma Drugs Market Size and Market Share by Mode Of Administration (2021-2023)
Table Asthma Drugs Market Size and Market Share by Treatment Type (2023-2030)
Figure Tablets and Capsules Market Size and Growth Rate (2021-2030) Figure Liquids Market Size and Growth Rate (2021-2030) Figure Inhalers Market Size and Growth Rate (2021-2030) Figure Injections Size and Growth Rate (2021-2030)
Table Asthma Drugs Market Size and Market Share by Organization Type (2021-2023)
Table Asthma Drugs Market Size and Market Share by Organization Type (2023-2030)
Figure Public Market Size and Growth Rate (2021-2030) Figure Private Market Size and Growth Rate (2021-2030)
Table Asthma Drugs Market by Regions (2021-2023)
Table Asthma Drugs Market by Regions (2023-2030) Figure North America Asthma Drugs Market Size and Growth Rate (2021-2030)
Table North America Asthma Drugs Market by Type (2021-2023) Table North America Asthma Drugs Market by Type (2023-2030)
Table North America Asthma Drugs by Application (2021-2023)
Table North America Asthma Drugs by Application (2023-2030)
Table North America Asthma Drugs by Country (2021-2023)
Table North America Asthma Drugs by Country (2023-2030) Figure United States Asthma Drugs Market Size and Growth Rate (2021-2030)
Table United States Asthma Drugs Market by Type (2021-2023) Table United States Asthma Drugs Market by Type (2023-2030)
Table United States Asthma Drugs by Application (2021-2023)
Table United States Asthma Drugs by Application (2023-2030) Figure Canada Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Canada Asthma Drugs Market by Type (2021-2023) Table Canada Asthma Drugs Market by Type (2023-2030)
Table Canada Asthma Drugs by Application (2021-2023)
Table Canada Asthma Drugs by Application (2023-2030) Figure Europe Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Europe Asthma Drugs Market by Type (2021-2023) Table Europe Asthma Drugs Market by Type (2023-2030)
Table Europe Asthma Drugs by Application (2021-2023)
Table Europe Asthma Drugs by Application (2023-2030)
Table Europe Asthma Drugs by Country (2021-2023)
Table Europe Asthma Drugs by Country (2023-2030) Figure Germany Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Germany Asthma Drugs Market by Type (2021-2023) Table Germany Asthma Drugs Market by Type (2023-2030)
Table Germany Asthma Drugs by Application (2021-2023)
Table Germany Asthma Drugs by Application (2023-2030) Figure France Asthma Drugs Market Size and Growth Rate (2021-2030)
Table France Asthma Drugs Market by Type (2021-2023) Table France Asthma Drugs Market by Type (2023-2030)
Table France Asthma Drugs by Application (2021-2023)
Table France Asthma Drugs by Application (2023-2030) Figure UK Asthma Drugs Market Size and Growth Rate (2021-2030)
Table UK Asthma Drugs Market by Type (2021-2023) Table UK Asthma Drugs Market by Type (2023-2030)
Table UK Asthma Drugs by Application (2021-2023)
Table UK Asthma Drugs by Application (2023-2030) Figure Russia Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Russia Asthma Drugs Market by Type (2021-2023) Table Russia Asthma Drugs Market by Type (2023-2030)
Table Russia Asthma Drugs by Application (2021-2023)
Table Russia Asthma Drugs by Application (2023-2030) Figure Italy Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Italy Asthma Drugs Market by Type (2021-2023) Table Italy Asthma Drugs Market by Type (2023-2030)
Table Italy Asthma Drugs by Application (2021-2023)
Table Italy Asthma Drugs by Application (2023-2030) Figure Rest of Europe Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Rest of Europe Asthma Drugs Market by Type (2021-2023) Table Rest of Europe Asthma Drugs Market by Type (2023-2030)
Table Rest of Europe Asthma Drugs by Application (2021-2023)
Table Rest of Europe Asthma Drugs by Application (2023-2030) Figure Asia-Pacific Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Asia-Pacific Asthma Drugs Market by Type (2021-2023) Table Asia-Pacific Asthma Drugs Market by Type (2023-2030)
Table Asia-Pacific Asthma Drugs by Application (2021-2023)
Table Asia-Pacific Asthma Drugs by Application (2023-2030)
Table Asia-Pacific Asthma Drugs by Country (2021-2023)
Table Asia-Pacific Asthma Drugs by Country (2023-2030) Figure China Asthma Drugs Market Size and Growth Rate (2021-2030)
Table China Asthma Drugs Market by Type (2021-2023) Table China Asthma Drugs Market by Type (2023-2030)
Table China Asthma Drugs by Application (2021-2023)
Table China Asthma Drugs by Application (2023-2030) Figure Japan Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Japan Asthma Drugs Market by Type (2021-2023) Table Japan Asthma Drugs Market by Type (2023-2030)
Table Japan Asthma Drugs by Application (2021-2023)
Table Japan Asthma Drugs by Application (2023-2030) Figure Korea Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Korea Asthma Drugs Market by Type (2021-2023) Table Korea Asthma Drugs Market by Type (2023-2030)
Table Korea Asthma Drugs by Application (2021-2023)
Table Korea Asthma Drugs by Application (2023-2030) Figure India Asthma Drugs Market Size and Growth Rate (2021-2030)
Table India Asthma Drugs Market by Type (2021-2023) Table India Asthma Drugs Market by Type (2023-2030)
Table India Asthma Drugs by Application (2021-2023) Table India Asthma Drugs by Application (2023-2030) Figure Southeast Asia Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Southeast Asia Asthma Drugs Market by Type (2021-2023) Table Southeast Asia Asthma Drugs Market by Type (2023-2030)
Table Southeast Asia Asthma Drugs by Application (2021-2023)
Table Southeast Asia Asthma Drugs by Application (2023-2030) Figure Rest of Asia-Pacific Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Rest of Asia-Pacific Asthma Drugs Market by Type (2021-2023) Table Rest of Asia-Pacific Asthma Drugs Market by Type (2023-2030)
Table Rest of Asia-Pacific Asthma Drugs by Application (2021-2023)
Table Rest of Asia-Pacific Asthma Drugs by Application (2023-2030) Figure South America Asthma Drugs Market Size and Growth Rate (2021-2030)
Table South America Asthma Drugs Market by Type (2021-2023) Table South America Asthma Drugs Market by Type (2023-2030)
Table South America Asthma Drugs by Application (2021-2023)
Table South America Asthma Drugs by Application (2023-2030)
Table South America Asthma Drugs by Country (2021-2023)
Table South America Asthma Drugs by Country (2023-2030) Figure Brazil Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Brazil Asthma Drugs Market by Type (2021-2023) Table Brazil Asthma Drugs Market by Type (2023-2030)
Table Brazil Asthma Drugs by Application (2021-2023)
Table Brazil Asthma Drugs by Application (2023-2030) Figure Mexico Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Mexico Asthma Drugs Market by Type (2021-2023) Table Mexico Asthma Drugs Market by Type (2023-2030)
Table Mexico Asthma Drugs by Application (2021-2023)
Table Mexico Asthma Drugs by Application (2023-2030) Figure Columbia Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Columbia Asthma Drugs Market by Type (2021-2023) Table Columbia Asthma Drugs Market by Type (2023-2030)
Table Columbia Asthma Drugs by Application (2021-2023)
Table Columbia Asthma Drugs by Application (2023-2030) Figure Rest of South America Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Rest of South America Asthma Drugs Market by Type (2021-2023) Table Rest of South America Asthma Drugs Market by Type (2023-2030)
Table Rest of South America Asthma Drugs by Application (2021-2023)
Table Rest of South America Asthma Drugs by Application (2023-2030) Figure Middle East and Africa Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Middle East and Africa Asthma Drugs Market by Type (2021-2023) Table Middle East and Africa Asthma Drugs Market by Type (2023-2030)
Table Middle East and Africa Asthma Drugs by Application (2021-2023)
Table Middle East and Africa Asthma Drugs by Country (2021-2023)
Table Middle East and Africa Asthma Drugs by Country (2023-2030) Figure Saudi Arabia Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Saudi Arabia Asthma Drugs Market by Type (2021-2023) Table Saudi Arabia Asthma Drugs Market by Type (2023-2030)
Table Saudi Arabia Asthma Drugs by Application (2021-2023)
Table Saudi Arabia Asthma Drugs by Application (2023-2030) Figure United Arab Emirates Asthma Drugs Market Size and Growth Rate (2021-2030)
Table United Arab Emirates Asthma Drugs Market by Type (2021-2023) Table United Arab Emirates Asthma Drugs Market by Type (2023-2030)
Table United Arab Emirates Asthma Drugs by Application (2021-2023)
Table United Arab Emirates Asthma Drugs by Application (2023-2030) Figure South Africa Asthma Drugs Market Size and Growth Rate (2021-2030)
Table South Africa Asthma Drugs Market by Type (2021-2023) Table South Africa Asthma Drugs Market by Type (2023-2030)
Table South Africa Asthma Drugs by Application (2021-2023)
Table South Africa Asthma Drugs by Application (2023-2030) Figure Rest of Middle East and Africa Asthma Drugs Market Size and Growth Rate (2021-2030)
Table Rest of Middle East and Africa Asthma Drugs Market by Type (2021-2023) Table Rest of Middle East and Africa Asthma Drugs Market by Type (2023-2030)
Table Rest of Middle East and Africa Asthma Drugs by Application (2021-2023)
Table Rest of Middle East and Africa Asthma Drugs by Application (2023-2030)
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Endoluminal Surgery and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue in U.S. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Endoluminal Surgery for the past year and forecasts for the next six years. The Global Endoluminal Surgery Market market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Endoluminal Surgery categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Endoluminal Surgery from different application industries in different regions.
Market Segmentation By Medication Quick Relief Medications Long-term Control Medications Others
By Mode of Administration Tablets and Capsules Liquids Inhalers Injections
By Organization Type Public Private
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
